Australian Longevity Clinic

Descriptions are written once in the variis service glossary and reused, so the same service reads the same way at every clinic. They describe what a service is, not whether it works: evidence is graded on the linked protocol.

• NAD+ and precursor therapy

  Intervention

  Administers NAD+ intravenously, or its precursors NMN or NR orally, to raise NAD+ availability. Regulatory status of the precursors differs between Singapore and Australia.

• GLP-1 receptor agonist therapy

  Intervention

  Prescribes semaglutide, tirzepatide or a related agent for weight and metabolic management, with clinical monitoring. These are prescription-only medicines in both markets.

• Peptide therapy

  Intervention

  Prescribes short amino-acid chains for signalling effects. Many peptides used in this setting are unapproved for the indication in one or both markets, so the regulatory position matters case by case.

• Hormone optimisation

  Intervention

  Assesses and treats sex and thyroid hormone levels, including menopausal hormone therapy and testosterone replacement, under prescription and monitoring.